AstraZeneca/Daiichi Sankyo’s Next ADC Shows Promise In Triple-Negative Breast Cancer
Aiming To Overhaul Gilead’s Trodelvy
Executive Summary
Having established Enhertu as their first antibody-drug conjugate blockbuster, AstraZeneca and Daiichi Sankyo are looking to challenge Gilead in the TROP2-targeting field as well.
You may also be interested in...
Amgen And Synaffix Alliance Could Be Biggest Preclinical ADC Licensing Deal Yet
Amgen has signed two big early-stage deals in a matter of days, signalling that antibody-drug conjugates are a priority target in oncology for the firm.
AZ Bets Big On ADCs As It Inks Second, $6bn Deal With Daiichi
Following their original March 2019 tie-up for an oncology antibody-drug conjugate, Daiichi Sankyo and AstraZeneca have entered into a new global deal worth up to $6bn for a second novel asset from the Japanese firm, with potential in breast, lung and other cancers.
Novartis Nominates Ex-BMS Chief As It Pursues US Growth Strategy
The Swiss pharma company is looking to tap into the experience of ex-BMS leader Giovanni Caforio to help further it US-first commercial strategy.